Dawnrays Pharmaceutical (02348) said its profit attributable to owners of the parent for the year ended 31 December 2016 dropped 12% year-on-year to Rmb266 million.
Basic and diluted earnings per share were Rmb33.14 cents and Rmb33.12 cents.
The revenue was Rmb824 million, a decrease of 16.3% from a year earlier.
The gross profit fell 10.2% year-on-year to Rmb511 million. Gross profit margin increased by 4.2 percentage points to 62% from 57.8% as in last year. It was mainly due to the influence of increased sales proportion of system specific medicines.
The proposed final dividend is HK10 cents (2015: HK12 cents) per share, payable on 13 June 2017.
全新節目《說說心理話》青少年不可以戀愛！？真實個案講述驚心動魄經歷► 即睇
